Dear Jeremy Powell,

Target Ovarian Cancer has no comment regarding the technical components of the report received regarding **Multiple Technology Appraisal (MTA)**

Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating cancer-treatment induced anaemia (including review of TA142).

We would like to state that we do welcome the opportunity that NICE is taking to assess the use of ESAs for treating cancer treatment induced anaemia.

Warm regards,

[redacted]

[redacted]

Professional Support Manager

Target Ovarian Cancer

My working days are Tuesday to Friday only

30 Angel Gate

London

EC1V 2PT

Tel: 0207 923 5470

Fax: 0207 923 5471